| |
| SUNDAY, June 22, 2008 |
| 7:45 am 8:00 am |
|
Welcome Address |
| 8:00 am - 10:00 am |
|
Multimodality Session I:
Co-Chairs: Mike Choti, Jordan Berlin, Daniel Brown, Luigi Solbiati
COLORECTAL LIVER METASTASES
| 1. |
Systemic Chemotherapy in Colorectal Cancer: Advances and Integration with Locoregional Therapy
Jordan Berlin |
| 2. |
Expanding the Role of Liver Resection in the Management of Liver Metastases
Michael Choti |
| 3. |
Intraoperative Ablation: Indications and Results
Sandra Wong |
| 4. |
Percutaneous Ablation of Liver Metastases
Luigi Solbiati |
| 5. |
Transarterial Chemoembolization for Hepatic Colorectal Metastases
Thierry Debaere |
| 6. |
Transarterial Radioembolization for Colorectal Metastases
Riad Salem |
| 7. |
Selected ASCO/WCIO Abstracts and/or Q&A |
|
| 10:00 am - 10:30 am |
|
Coffee Break
(Exhibit Hall) |
| 10:30 am - 11:45 am |
|
Multimodality Session II:
Co-Chairs: Yuman Fong, Mike Wallace & Alice Gillams
NON-COLORECTAL LIVER METASTASES
| 1. |
Neuroendocrine and Other Non-Colorectal Hepatic Metastases: Medical Management And Rationale for Loco-Regional Therapy
Al Benson |
| 2. |
Neuroendocrine and Other Non-Colorectal Hepatic Metastases: Surgical Management
Yuman Fong |
| 3. |
Neuroendocrine and Other Non-Colorectal Hepatic Metastases: Transarterial Therapy
Michael Wallace |
| 4. |
Neuroendocrine and Other Non-Colorectal Hepatic Metastases: Ablative Therapy
Alice Gillams |
| 5. |
Selected ASCO/WCIO Abstract and/or Q&A |
|
| 11:45 am - 12:30 pm |
|
Multimodality Session III: LIVER METASTASES TUMOR BOARD
Co-Chairs: Bill Lees, Al Benson, Yuman Fong |
| 12:30 pm - 1:30 pm |
|
Lunch Break & Poster Viewing |
| 1:30 pm - 3:30 pm |
|
Basic Science and Technology Session I:
Co-Chairs: Stephen Solomon & Fred Lee
ADVANCES IN ENERGY BASED AND EMBOLIC THERAPIES
Tissue Ablation:
| 1. |
Basic Science and Advances in Thermal Ablation
Chris Brace |
| 2. |
Basic Science and Advances in Cryotherapy
Peter Littrup |
| 3. |
Basic Science and Advances in HIFU
Fiona Fennessy |
| 4. |
Basic Science and Advances in Irreversible Electroporation
Boris Rubinsky |
| 5. |
Stereotactic radiosurgery/IMR/IGRT
Thomas Mackie |
Trans-arterial Therapy:
| 6. |
Biology and Advances in Drug Eluting Beads
Peter Stratford |
| 7. |
Radio-Embolization: Foundation and Future
Andrew Kennedy |
| 8. |
New Intra-Arterial Chemotherapeutics
Jeff Geschwind |
| 9. |
Oncolytic Viruses and Novel Agents
Anthony Reid |
| 10. |
Selected ASCO/WCIO Abstract and/or Q&A |
|
| 1:30 pm - 3:30 pm |
|
Concurrent ONCOLOGY SESSION I: BEST OF ASCO
| 1. |
Welcome and Introductions - Mark Pegram, Masakatsu Toi
|
| |
| 2. |
Gastrointestinal Colorectal Cancers - Al Benson
Randomized phase III study of capecitabine, oxaliplatin and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)
Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU+irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301)
KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience
Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials.
|
| |
| 3. |
Gastrointestinal Non-Colorectal Cancers - Jordan Berlin
CONKO-001: Final Results of the randomized, prospective, multicenter phase 3 trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer (PC)
A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907)
A randomized, double blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer
Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma
A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201
|
| |
| 4. |
Genitourinary Cancers - William Figg
RAD001 plus best supportive care (BSC) vs BSC plus placebo in patients with metastatic renal cell carcinoma (RCC), which has progressed on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter Phase-3 study
Radiotherapy versus Carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomised trial (ISRCTN27163214)
Abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, has significant and durable anti-tumor activity in both chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC)
Impact of Androgen Deprivation Therapy (ADT) on bone, cardiovascular, and endocrine outcomes: a propensity-matched analysis of 20,000 patients
|
| |
|
| 3:30 pm - 4:00 pm |
|
Refreshment Break
(Exhibit Hall) |
| 4:00 pm - 5:30 pm |
|
IO TREATMENT STRATEGIES Session I: LIVER METASTASES
Co-Chairs: Riad Salem & Fred Lee
Percutaneous ablation of liver metastases:
| 1. |
Patient Selection and Anatomic Considerations
Fred Lee |
| 2. |
Optimizing RFA Technique
Alice Gillams |
| 3. |
Ct/Us In Ablation Guidance and Monitoring
Louis Hinshaw |
| 4. |
Post Ablation Imaging and Management
Philippe Pereira |
Transcatheter therapy of liver metastases:
| 1. |
Portal Vein Embolization
David Madoff |
| 2. |
Bland Embolization
Karen Brown |
| 3. |
Chemoembolization
Daniel Sze |
| 4. |
Radioembolization
Jose Bilbao |
| 5. |
Chemo-infusion
Yasuaki Arai |
| 6. |
Debate on Trans-arterial Techniques |
|
| 4:00 pm - 5:30 pm |
|
Concurrent ONCOLOGY SESSION II: BEST OF ASCO
| 1. |
Breast Cancer - Local Regional Adjuvant Therapy Peter Ravdin
Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12
Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older. Results of CALGB/CTSU 49907
Vitamin D (Vit D) deficiency is common at breast cancer (BC) diagnosis and is associated with a significantly higher risk of distant recurrence and death in a prospective cohort study of T1-3, N0-1, M0 BC
tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early stage breast cancer (EBC)
Zoledronic Acid (ZA) preserves bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809
|
| |
| 2. |
Breast Cancer - Metastatic - Mark Pegram
Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO
A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy
TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple negative (basal-like) breast cancer
Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population based database and tissue microarray series
|
| |
| 3. |
Melanoma - Donald Morton
Final results of the Sunbelt Melanoma Trial
Sentinel lymph node biopsy (SLNB) improves survival among SEER patients with melanoma
|
| |
|
| 6:00 pm - 7:30 pm |
|
Welcome Reception |
| 7:30 pm - 9:30 pm |
|
AngioDynamics Symposium - Novel Thermal and Non-Thermal Ablation Techniques in the Management of Malignancies |
| |
| MONDAY, June 23, 2008 |
| 7:00 am - 8:00 am |
|
Ablation Workshop |
| 8:00 am - 10:00 am |
|
Multimodality Session IV: LUNG MALIGNANCIES
Co-Chairs: Steven Rose, Thomas DePetrillo, Hiran Fernando, Thomas Lynch
NON-SMALL CELL LUNG CANCER
| 1. |
NSCLC: Overview of Staging and Medical Therapy
Lyudmila Bazhenova |
| 2. |
NSCLC: Surgical Resection, Indication and Results
Hiran Fernando |
| 3. |
NSCLC: Percutaneous RFA: Indication and Results
Steven Rose |
| 4. |
NSCLC: Alternative Ablative Therapies
Damian Dupuy |
| 5. |
NSCLC: Radiation Therapy with/without Ablation: Indications and Results
Tom Dipetrillo |
| 6. |
NSCLC: Q&A and/or Selected ASCO/WCIO Abstract |
LUNG METASTASES
| 7. |
Lung Metastases: Role of Surgical Resection
Garrett Walsh |
| 8. |
Lung Metastases: Role of Ablative Therapy
Koichiro Yamakado |
| 9. |
Lung Metastases: Q&A and/or Selected ASCO/WCIO Abstract |
|
| 10:00 am - 10:30 am |
|
Coffee Break
(Exhibit Hall) |
| 10:30 am - 11:00 am |
|
Multimodality Session V: LUNG TUMOR BOARD
Co-chairs: Damian Dupuy, Roberto Orrechia, Garrett Walsh |
| 11:00 am - 12:00 pm |
|
Multimodality Session VI: BONE METASTASES AND PAIN PALLIATION
Co-Chairs: Matthew Callstrom & Nora Janjan
| 1. |
Medical and Surgical Management and Rationale for Loco-regional Therapies
Thomas Smith |
| 2. |
Radiation Therapy of Painful Bone Metastases
Nora JanJan |
| 3. |
RFA of Painful Bone Metastasis
Damian Dupuy |
| 4. |
Cryoablation and Stabilization of Painful Bone Metastases
Matthew Callstrom |
| 5. |
Ablation and Stabilization of Vertebral Body Tumors
Afsin Gangi |
| 6. |
Selected ASCO/WCIO Abstract and/or Q&A |
|
| 12:00 pm - 12:30 pm |
|
Keynote Speaker
|
| 12:30 pm - 1:30 pm |
|
Lunch Break & Poster Viewing
(Exhibit Hall) |
| 1:30 pm - 3:30 pm |
|
Basic Science and Technology Session II:
ADVANCES IN IMAGE GUIDANCE AND MONITORING
Co-Chairs: Philippe Pereira, Luigi Solbiati, Bradford Wood
| 1. |
Advances in Interventional US (Contrast Agents, Real-time Fusion Imaging)
Luigi Solbiati |
| 2. |
Advances in 3D Fluoroscopy
Marshall Hicks |
| 3. |
Advances in Interventional CT
Thomas Helmberger |
| 4. |
Advances in Interventional MRI (guidance, monitoring, assessment)
Philippe Pereira |
| 5. |
Newest Technological Advancements (Multimodality Imaging, Robotics)
Bradford Wood |
| 6. |
Role of Molecular Imaging in Image Guided Intervention
TBD |
| 7. |
Two Selected Abstracts and/or Q&A |
|
| 1:30 PM - 3:30 PM |
|
Concurrent ONCOLOGY SESSION III: BEST OF ASCO
| 1. |
Lung Cancer - David Gandara
S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC)
Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED-SCLC): final results of a randomised phase III trial
Phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC): Interim results
Randomized trial of standard dose to a higher dose prophylactic cranial irradiation (PCI) in limited-stage small cell cancer (SCLC) complete responders (CR): Primary end-point analysis (PCI99-01, IFCT 99-01, EORTC 22003-08004, RTOG 0212)
FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC)
A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients
Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study
|
| |
| 2. |
Patient and Survivor Care - Patricia Ganz
A Phase III randomized, placebo-controlled, double-blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP Study
Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer
Cardiovascular disease in adult survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study (CCSS)
Management recommendations for women at increased familial risk for breast cancer: Results of a prospective national multi-modality cohort study
|
| |
| 3. |
Gynecologic Cancers - Maurie Markman
Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology
AZD2281 (KU-0059436), a PARP (Poly ADP-ribose Polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a Phase I study
|
| |
|
| 3:30 pm - 4:00 pm |
|
Refreshment Break
(Exhibit Hall) |
| 4:00 pm - 5:30 pm |
|
IO TREATMENT STRATEGIES Session II:
LUNG AND METASTATIC BONE TUMORS
Lung Tumors:
Co-Chairs: Robert Suh, Steven Rose
| 1. |
Patient Selection and Evaluation
Karin Steinke |
| 2. |
Optimizing Ablative Technique
Damian Dupuy |
| 3. |
Clinical and Imaging Follow-up
Robert Suh |
| 4. |
Complications and Management
Kamran Ahrar |
Bone and Soft Tissue Tumors
Chair: William Charboneau
| 5. |
Vertebral Body
Antonio Basile |
| 6. |
Bone
William Charboneau |
|
| 4:00 pm - 5:30 pm |
|
Concurrent ONCOLOGY SESSION IV: BEST OF ASCO
| 1. |
Lymphoma/Leukemia/Myeloma TBD
Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups
International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma
A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF)
Azacitidine (AZA) extends overall survival in higher-risk myelodysplastic syndromes (MDS) without necessity for complete remission
Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)
Total therapy (TT) for myeloma (MM): 10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2
Bortezomib/Dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial
|
| |
| 2. |
Developmental Therapeutics - TBD
A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors
A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an Insulin Like Growth Factor-1 Receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors
|
| |
|
| |
| TUESDAY, June 24, 2008 |
| 7:00 am - 8:00 am |
|
Image Guidance Workshop |
| 8:00 am - 10:00 am |
|
Multimodality Session VII:
HEPATOCELLULAR CARCINOMA
Co-Chairs : Riccardo Lencioni, Ronald Busuttil, Jeff Geschwind, Myron Tong
| 1. |
Clinical Overview and Natural History
Myron Tong |
| 2. |
Surgical Resection: Patient Selection and Outcomes
Nicolas Vauthey |
| 3. |
Transplantation: Patient Selection and Outcomes
Ronald Busuttil |
| 4. |
TAE/TACE: Indications and Outcomes
William Rilling |
| 5. |
TACE with Drug Eluting Beads
Jeff Geschwind |
| 6. |
Radioembolization: Indications and Outcomes
Riad Salem |
| 7. |
Percutaneous Chemical Ablation: Indications and Outcomes
Michael Soulen |
| 8. |
Percutaneous Thermal Ablation: Indications and Outcomes
Gerald Dodd |
| 9. |
Role of Loco-regional Therapies as Bridge to Transplant
David Lu |
| 10. |
Combining Transarterial and Ablative Therapies
Riccardo Lencioni |
| 11. |
Integrating HCC Management with Loco-regional and Advances in Systemic Therapies
TBD |
| 12. |
Q & A |
|
| 10:00 am - 10:30 am |
|
Coffee Break
(Exhibit Hall) |
| 10:30 am - 11:00 am |
|
Multimodality Session VIII:
HEPATOCELLULAR CARCINOMA (CONTINUED)
| 13. |
Selected ASCO/WCIO Abstracts |
|
| 11:00 am - 12:00 pm |
|
Multimodality Session IX:
HCC INTERNATIONAL TUMOR BOARD
Co-Chairs: Riccardo Lencioni, Jordan Berlin, Marisato Sato, Nicolas Vauthey |
| 12:00 pm - 12:30 pm |
|
Keynote Lecture
King C. Li, MD |
| 12:30 pm - 1:30 pm |
|
Lunch Break & Poster Viewing
(Exhibit Hall) |
| 1:30 pm - 3:30 pm |
|
IO TREATMENT STRATEGIES Session III:
TRANSARTERIAL THERAPY FOR HCC
Co-Chairs: William Rilling, Yasuaki Arai, Ren-jie Yang
| 1. |
Clinical Evaluation and Patient Selection in Transarterial Therapies for HCC
William Rilling |
| 2. |
HCC Treatment Planning and Endpoint Determination with CTA and CTAP
Yasuaki Arai |
| 3. |
TACE for HCC: Optimizing Technique
Jae-Hyung Park |
| 4. |
TACE and Interventional Management in Advanced, Complicated HCC
Ren-jie Yang |
| 5. |
Y 90 Radioembolization for HCC: Optimizing Technique
Jose Bilbao |
| 6. |
Complications and Management of Transarterial Therapies
Daniel Brown |
| 7. |
Post Therapy Imaging and Follow Up:
| a. | Post TAE/TACE
TBD |
| b. | Post radioembolization
Robert Lewandowsky |
|
| 8. |
Selected Abstracts and/or Q&A |
|
| 1:30 pm - 3:30 pm |
|
Concurrent ONCOLOGY SESSION V:
TISSUE GENE/MOLECULAR PROFILING & TARGETTED THERAPIES
Co-Chairs: Mark Pegram, Gary Dorfman, James Economou
| 1. |
Introduction an Oncologic Overview
Mark Pegram |
| 2. |
What is the Opportunity, What Are the Barriers
Gary S. Dorfman |
| 3. |
Advances in Biopsy Techniques
Brad J. Wood |
| 4. |
Advances in Biospecimen Analysis
TBD |
| 5. |
Linking In Vitro and In Vivo Data: Imaging Phenotypes
Michael Kuo |
| 6. |
The Role of Biospecimen Analysis in Guiding Targeted Therapies
TBD |
| 7. |
Panel Discussion, Q & A |
|
| 3:00 pm - 4:00 pm |
|
Refreshment Break
(Exhibit Hall) |
| 4:00 pm - 5:30 pm |
|
IO TREATMENT STRATEGIES Session IV:
ABLATIVE THERAPY FOR HCC
Co-Chairs: Gerald Dodd & Hyo Keun Lim
| 1. |
Imaging Criteria and Biopsy in Diagnosis of HCC
Steve Raman |
| 2. |
Alcohol Ablation - Optimizing technique
Chia Sing Ho |
| 3. |
Thermal Ablation - Optimizing Technique
Hyuncul Rhim |
| 4. |
Advanced Ablation Strategies in Difficult Cases
David Lu |
| 5. |
Complications and Management of Percutaneous Ablations
Gerald Dodd |
| 6. |
Post RFA Imaging
Hyo Keun Lim |
| 7. |
Selected Abstracts and/or Q&A |
|
| 4:00 pm - 5:30 pm |
|
Concurrent ONCOLOGY SESSION VI:
Co-Chairs: Gary Dorfman & Mark Pegram
| 1. |
Additional ASCO highlights |
| 2. |
Clinical Trials Update |
|
| 5:30 pm - 6:30 pm |
|
Focus Session: Bridge to China 2009
Co-Chairs: Ren Jie Yang, David Lu
| 1. |
New advances of microwave ablation in China
Ping Liang |
| 2. |
RFA vs surgery in the treatment of small HCC
Ming Shan Chen |
| 3. |
Role of RFA in the treatment of large HCC
Ming Hua Chen |
| 4. |
Ethanol ablation of HCC with multi-pronged injection
Xiao Yan Xie |
| 5. |
TACE in prevention and treatment of postoperative recurrence of HCC
Sheng Long Ye |
| 6. |
TAE with iodized oil and pingyangmycin for hemangiomas of liver
Ke Xu |
| 7. |
Percutaneous cryoablation of non small cell lung cancer
Ji Ren Zhang |
|
| |
| WEDNESDAY, June 25, 2008 |
| 7:00 am - 8:00 am |
|
Transarterial Therapy Workshop |
| 8:00 am - 10:00 am |
|
Multimodality Session X:
GENITOURINARY MALIGNANCIES
Co-Chairs: Debra Gervais, Surena Matin, Peter Mueller
Renal Cell Carcinoma and Renal Masses
| 1. |
Clinical Overview and Natural History
Robert Figlin |
| 2. |
Systemic Therapy
Robert Figlin |
| 3. |
Surgical Resection
Surena Matin |
| 4. |
RFA for RCC
David Breen |
| 5. |
Cryoablation for RCC
William Charboneau |
| 6. |
Transcatheter Embolization of Renal Masses
Kamran Ahrar |
IO in Other GU Malignancies
| 7. |
Percutaneous Adrenal Ablation
William Mayo-Smith |
| 8. |
Regional Radiation Therapy for Prostate Cancer
Thomas DiPetrillo |
| 9. |
Focal Ablative Therapy for Prostate Cancer
Gary Onik |
| 10. |
Role of Ablation in Ovarian Cancer
Debra Gervais |
| 11. |
Selected ASCO/WCIO Abstract and/or Q&A |
|
| 10:00 am - 10:30 am |
|
Coffee Break
(Exhibit Hall) |
| 10:30 am - 11:00 am |
|
Multimodality Session XI:
GENITOURINARY TUMOR BOARD
Co-Chairs: Kamran Ahrar & Surena Matin |
| 11:00 am - 12:30 pm |
|
MULTIMODALITY SESSION XII:
EXPLORING SYNERGIES: SYSTEMIC, LOCAL/REGIONAL, ENERGY, DRUGS, AND BIOLOGIC AGENTS
Co-Chairs: S. Nahum Goldberg, Thomas DiPetrillo, Keith Stuart, Michael Soulen
| 1. |
Enhancing Anti-tumoral Efficacy by Transarterial Delivery
Michael Soulen |
| 2. |
Targetted Energy Activation and Systemic Agents
S. Nahum Goldberg |
| 3. |
Antiangiogenesis and Minimal Invasive Therapy
Robert Figlin |
| 4. |
Thermal Ablation and Radiation Therapy
Tom DiPetrillo |
| 5. |
Immunologic Modulation and Interventional Oncology
Elizabeth Repasky |
| 6. |
The Case for Adding Focal Therapy to Medical Oncology Practice
Keith Stuart |
| 7. |
Selected abstracts and/or Q&A |
|
| 12:30 pm - 1:30 pm |
|
Lunch And Poster Viewing
(Exhibit Hall) |
| 1:30 pm - 2:30 pm |
|
Multimodality Session XIII:
Emerging IO Applications
Co-Chairs: John McGahan & Ross Abrams
| 1. |
Chemo-embolization Beyond Liver
Thomas J. Vogl |
| 2. |
Emerging Thermal Ablation Applications
John McGahan |
| 3. |
Emerging Cryo-ablation Applications
Peter Littrup |
| 4. |
Emerging IMRT Applications Ross Abrams |
| 5. |
HIFU Beyond Fibroids David Gianfelice |
| 6. |
Irreversible Electroporation: Early Tumor Data
Stephen Kee |
|
| 2:30 pm - 3:30 pm |
|
Multimodality Session XIV:
Selected ASCO/WCIO Abstracts
Chair: John McGahan |
| 3:30 pm - 4:00 pm |
|
Refreshment Break
(Exhibit Hall) |
| 4:00 pm - 5:30 pm |
|
IO TREATMENT STRATEGIES Session V:
GU Tumors
Co-Chairs: Debra Gervais, Steve Raman, Stuart Silverman
| 1. |
Treatment Planning
Steve Solomon |
| 2. |
Biopsy or No Biopsy Before Ablation
Stuart Silverman |
| 3. |
Cryoablation versus RF Ablation for Renal Masses
Steve Raman |
| 4. |
Size Matters: Upper and lower Limits of Renal Mass Ablation
Ronald Zagoria |
| 5. |
Avoiding and Managing Complications of Renal Ablation
Peter Mueller |
| 6. |
Imaging Follow Up after Renal Ablation: Basic Premises and Current Challenges
Debra Gervais |
|
| 4:00 pm - 5:30 pm |
|
IO TREATMENT STRATEGIES Session VI:
PRACTICE DEVELOPEMENT
Co-Chairs: Daniel Brown & Riad Salem
| 1. |
How to Set Up an IO Clinic
David Liu |
| 2. |
Role of Physician Extenders
Kelvin Hong |
| 3. |
Practice Building
Daniel Brown |
| 4. |
Practice Management
Riad Salem |
| 5. |
Managing an Inpatient Interventional Oncology Service
Tim Clark |
| 6. |
Whats New in Reimbursement
Catherine Tuite |
| 7. |
Q&A |
|
| 5:30 pm |
|
Adjourn |
